Frédéric Faure
Lyons
36 Papers
125 Citations
Frédéric Faure is an academic researcher from Lyons. The author has contributed to research in topics: Medicine & Sialography. The author has an hindex of 14, co-authored 35 publications.
Chat about Author
Papers
Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output
Sophie Dupuis-Girod,Isabelle Ginon,Jean-Christophe Saurin,Denis Marion,Elsa Guillot,Evelyne Decullier,Adeline Roux,Marie-France Carette,Brigitte Gilbert-Dussardier,Pierre-Yves Hatron,P. Lacombe,Bernard Lorcerie,Sophie Rivière,Romain Corre,Sophie Giraud,Sabine Bailly,Gilles Paintaud,David Ternant,Pierre-Jean Valette,Henri Plauchu,Frédéric Faure +20 more
TL;DR: Administration of bevacizumab was associated with a decrease in cardiac output and reduced duration and number of episodes of epistaxis in patients with HHT associated with severe hepatic vascular malformations and high cardiac output.
366
Juvenile recurrent parotitis: sialendoscopic approach.
Stephanie Quenin,Isabelle Plouin-Gaudon,Francis Marchal,Patrick Froehlich,F. Disant,Frédéric Faure +5 more
TL;DR: D Diagnostic sialendoscopy is a new procedure that can be used in children for reliable evaluation of salivary ductal disorders, with low morbidity, and appears to be a safe and effective method for treating JRP.
96
Pediatric Salivary Gland Obstructive Swelling: Sialendoscopic Approach
Frédéric Faure,Stephanie Querin,Pavel Dulguerov,Patrick Froehlich,François Disant,Francis Marchal +5 more
TL;DR: To assess the efficacy of sialendoscopy as a diagnostic and interventional procedure for salivary ductal pathologies of children, a large number of children with Salivary Ductal Pathologies are treated with this procedure.
Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial
Sophie Dupuis-Girod,Alexis Ambrun,Evelyne Decullier,Anne-Emmanuelle Fargeton,Adeline Roux,Valentine Bréant,Bettina Colombet,Sophie Rivière,César Cartier,P. Lacombe,Thierry Chinet,Sandra Blivet,Jean-Hugues Blondel,Brigitte Gilbert-Dussardier,Xavier Dufour,Justin Michel,Jean-Robert Harle,Patrick Dessi,Frédéric Faure +18 more
TL;DR: In patients with HHT, a bevacizumab nasal spray treatment of 3 administrations at 14-day intervals with doses of 25 mg, 50 mg, or 75 mg per spray, compared with a placebo, did not reduce monthly epistaxis duration in the 3 consecutive months immediately after the end of treatment.
Thulium-YAG laser sialendoscopy for parotid and submandibular sialolithiasis†‡
TL;DR: To evaluate the efficacy and safety of thulium‐YAG laser in sialendoscopic fragmentation of salivary lithiasis, a single laser is used for the first time in this clinical trial.
66